Clinical Research Papers:
Fertility-sparing uterine lesion resection for young women with gestational trophoblastic neoplasias: single institution experience
Metrics: PDF 1074 views | HTML 1382 views | ?
Xiaoyu Wang1, Junjun Yang1, Jie Li1, Jun Zhao1, Tong Ren1, Fengzhi Feng1, Xirun Wan1 and Yang Xiang1
1 Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China
Yang Xiang, email:
Keywords: gestational trophoblastic neoplasias; fertility-sparing surgery; uterine lesion resection; prognostic factor; pregnant outcomes
Received: November 02, 2016 Accepted: January 09, 2017 Published: January 18, 2017
Purpose: To evaluate the oncological safety and pregnant outcomes of fertility-sparing uterine lesion resection in treating gestational trophoblastic neoplasias.
Results: After the treatment of surgery and chemotherapy, all the patients achieved complete remission. With a median follow-up time of 44 months (range, 6-188), 3 patients (3.85%) relapsed within 3-26 months. Multivariate analysis showed that tumor size was the independent risk factor of recurrence and the cutoff value was 4.2cm. Among 37 patients who attempted to conceive, 31 achieved clinical pregnancy. The rate of pregnancy and live birth were 83.8% and 77.4%. Uterine rupture did not occurred no matter in cesarean section or vaginal delivery. No congenital abnormalities were reported among the live births.
Methods: From January 1995 to December 2014, 78 patients with gestational trophoblastic neoplasias who underwent fertility-sparing uterine lesion resection at Peking Union Medical College Hospital were reviewed. The complete remission rate, fertility rate, pregnant outcomes and risk factors of recurrence were analyzed.
Conclusions: Fertility-sparing uterine lesion resection might be considered as a safe and reasonable alternative for high-selected young women to remove uterine lesion in the treatment of gestational trophoblastic neoplasias.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.